Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Yu, H. A. [1 ]
Cantero, F. [2 ]
Kim, B. [3 ]
Lee, M. [4 ]
Wu, E. [5 ]
Sternberg, D. W. [6 ]
Janne, P. A. [7 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA
[3] Daiichi Sankyo Inc, Clin Sci, Basking Ridge, NJ USA
[4] Daiichi Sankyo Inc, Quantitat Clin Pharmacol, Basking Ridge, NJ USA
[5] Daiichi Sankyo Inc, Biostat, Basking Ridge, NJ USA
[6] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA
[7] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1313
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1190TiP
引用
收藏
页码：S1092 / S1093
页数：2
相关论文
共 50 条
  • [21] Repeated biopsy for mutational analysis on EGFR-mutated non-small cell lung cancer (EGFR-NSCLC): Feasibility and safety
    Anguera, G.
    Riudavets, M.
    Torrego, A.
    Pajares, V.
    Gimenez, A.
    Lopez-Vilaro, L.
    Martinez, E.
    Trujillo-Reyes, J. C.
    Lerma, E.
    Majem, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Plasma metabolite biomarkers for EGFR-mutated non-small cell lung cancer (NSCLC)
    Thamlikitkul, Lucksamon
    Manocheewa, Siriphan
    Limjiasahapong, Suphitcha
    Wanichthanarak, Kwanjeera
    Panya, Atikorn
    Poungvarin, Naravat
    Pomyen, Yotsawat
    Khoomrung, Sakda
    CANCER RESEARCH, 2024, 84 (06)
  • [23] Patritumab Deruxtecan Is Efficacious in EGFR-Mutant Non-Small Cell Lung Cancer
    Zhang, H.
    Yu, X.
    Ye, J.
    Li, H.
    Hu, J.
    Tan, Y.
    CANCER DISCOVERY, 2023, 13 (12) : 2501 - 2501
  • [24] Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01
    Johnson, M. L.
    Janne, P. A.
    Goto, Y.
    Yoh, K.
    Lee, S-H.
    Paz-Ares, L.
    Besse, B.
    Novello, S.
    Hayashi, H.
    Kim, D-W.
    John, T.
    Kao, S. C-H.
    Felip, E.
    Yang, J. C-H.
    Reck, M.
    Dong, Q.
    Sporchia, A.
    Sternberg, D. W.
    Yu, H. A.
    ANNALS OF ONCOLOGY, 2023, 34
  • [25] Treatment strategy of EGFR-mutated non-small cell lung cancer
    Tanaka, Fumihiro
    Yoneda, Kazue
    Takenaka, Masaru
    Kuroda, Koji
    JOURNAL OF THORACIC DISEASE, 2022, 14 (03) : 602 - 606
  • [26] Emerging drugs for EGFR-mutated non-small cell lung cancer
    Sukrithan, Vineeth
    Deng, Lei
    Barbar, Alexander
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (01) : 5 - 16
  • [27] How to Treat EGFR-Mutated Non-Small Cell Lung Cancer
    Belani, Neel
    Liang, Katherine
    Fradley, Michael
    Judd, Julia
    Borghaei, Hossein
    JACC: CARDIOONCOLOGY, 2023, 5 (04): : 542 - 545
  • [28] Systemic treatment of EGFR-mutated non-small cell lung cancer
    Czyzykowski, Rafal L.
    Wrona, Ewa K.
    Talajko, Agata
    Hasinska, Aleksandra M.
    Potemski, Piotr J.
    ONCOLOGY IN CLINICAL PRACTICE, 2024,
  • [29] Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism
    Hotta, Takamasa
    Tsubata, Yukari
    Hamai, Kosuke
    Tanino, Akari
    Kobayashi, Misato
    Nakamura, Atsushi
    Sugisaka, Jun
    Hongoh, Masafumi
    Ishihara, Noriyuki
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Fujitaka, Kazunori
    Kubota, Tetsuya
    Nishimura, Nobuhiro
    Isobe, Takeshi
    RESPIRATORY INVESTIGATION, 2021, 59 (03) : 327 - 334
  • [30] Estrogen Metabolism in Patients with EGFR-Mutated and ALK-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Bodor, J. N.
    Treat, J.
    Krzizike, D. D.
    Zawislak, C. L.
    Vanderveer, L.
    Yulis, M.
    Chau, A.
    Ross, E. A.
    Andrews, A. J.
    Clapper, M. L.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S18 - S19
12345